OpenScience.ink

2 weeks ago • American journal of epidemiology

Different treatment responses to GLP-1 receptor drugs in people with type 2 diabetesExploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes.

🥉 Top 5% JournalArticle

2 weeks ago • BMJ open

📖 Top 20% JournalArticle

2 weeks ago • Kidney international

Safety of semaglutide in people with different levels of chronic kidney disease in the FLOW trialSafety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.

🥈 Top 2% JournalArticle

2 weeks ago • British journal of clinical pharmacology

How Elecoglipron is Absorbed in Healthy People When Taken With or Without FoodPhase 1, open-label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions.

📖 Top 20% JournalArticle

2 weeks ago • Endocrine reviews

How Gut Bacteria and Fat Hormones Relate to Insulin Resistance Through Helpful and Harmful FGF21 and GDF15 SignalsThe Microbiome-Metabolokine-Adipokine Axis in Insulin Resistance: Adaptive and Maladaptive FGF21-GDF15 Signaling.

🥇 Top 1% JournalArticle

2 weeks ago • The lancet. Diabetes & endocrinology

The progress of obesity medicine: from early problems to WHO approvalThe development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO.

🥇 Top 1% JournalArticle

2 weeks ago • Body image

Links between positive body image, feeling connected to the body, and thoughts about GLP-1 weight loss treatment in UK womenAssociations between positive body image, embodiment, and GLP-1 consideration for weight loss among women in the United Kingdom.

🥉 Top 5% JournalArticle

2 weeks ago • Journal of shoulder and elbow arthroplasty

Safety of diabetes drug use in non-diabetic overweight patients having shoulder replacement surgeryEvaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty.

📖 Top 30% JournalArticle

2 weeks ago • Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Timing of Starting and Stopping GLP-1 Treatment Around Tummy Tuck Surgery and Its Effects on Weight and ComplicationsPerioperative GLP-1 analog management in abdominoplasty: A multicenter comparative study of cessation and resumption timing on weight outcomes and complications.

📖 Top 30% JournalArticle

2 weeks ago • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Healthcare costs and savings after weight-loss surgery or medication for obesity and diabetes depend on insurance coverageTotal healthcare costs and cost savings after bariatric surgery and glucagon-like peptide-1 receptor agonist treatment for obesity and diabetes vary with insurance coverage.

📖 Top 20% JournalArticle

2 weeks ago • Kidney medicine

Key Treatments for Advanced Type 2 Diabetes and Severe Kidney Disease: Too Late or Still Possible to Start?Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible-or Not Too Late to Start?

📖 Top 20% JournalArticle

2 weeks ago • Clinical ophthalmology (Auckland, N.Z.)

Semaglutide use and risk of diabetic eye disease and optic nerve damage in type 2 diabetesSemaglutide Use and Risk of Diabetic Retinopathy and Non-Arteritic Anterior Ischemic Optic Neuropathy in Type 2 Diabetes: A Single-Center Retrospective Cohort Study.

📖 Top 20% JournalArticle

2 weeks ago • Alzheimer's & dementia (New York, N. Y.)

Effects of GLP-1 receptor drugs in Alzheimer's disease and mild memory problems: a combined analysisGLP-1 receptor agonists in Alzheimer's disease and MCI: a meta-analysis.

🥉 Top 5% JournalArticle

2 weeks ago • Diabetes

Incretin hormones influence the increase of neutrophils around meal timesAn Incretin-Dependent Modulation of Periprandial Neutrophilia.

🥉 Top 5% JournalArticle

2 weeks ago • The patient

Patients’ positive treatment experiences with Orforglipron compared to oral Semaglutide in type 2 diabetesQualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.

🎖️ Top 10% JournalArticle

2 weeks ago • Journal of the American Heart Association

Glucagon-Like Peptide-1 Drugs and New Heart Problems and Death in People with Serious Mental Illness, Type 2 Diabetes, and ObesityGlucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity.

🥉 Top 5% JournalArticle

2 weeks ago • Journal of internal medicine

Treating Excessive Eating and Obesity in Prader-Willi SyndromeTreatment of hyperphagia and obesity in Prader-Willi syndrome.

🥉 Top 5% JournalArticle

2 weeks ago • European journal of heart failure

Heart and blood vessel outcomes after aortic valve replacement linked to GLP-1 receptor agonist treatmentGLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational study.

🥇 Top 1% JournalArticle

2 weeks ago • Plastic and reconstructive surgery

Effects of GLP-1 Drugs on Recovery After Cosmetic and Body Shaping SurgeryImpact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-Analysis.

📖 Top 20% JournalArticle

2 weeks ago • Addictive behaviors

Semaglutide's effects and brain mechanisms in alcohol use disorderExploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms.

🎖️ Top 10% JournalArticle

2 weeks ago • Current atherosclerosis reports

GLP-1 Receptor Drugs and Lipoprotein (a): Understanding Their Role and Importance in Heart DiseasesGLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.

🎖️ Top 10% JournalArticle

2 weeks ago • The journal of knee surgery

Using GLP-1 Receptor Agonists Before Knee Replacement Surgery is Linked to Lower Risk of Heart Attack and Blood Clots After SurgeryGLP-1 Receptor Agonist Use Before Total Knee Arthroplasty is Associated With Lower Postoperative MI, DVT, and VTE Rates.

📖 Top 20% JournalArticle

2 weeks ago • Current opinion in pharmacology

Polycystic Ovary Syndrome: Understanding Causes, Current Treatments, and New TherapiesPolycystic ovary syndrome: An insight into pathophysiology, current management, and emerging therapeutic approaches.

🎖️ Top 10% JournalArticle

2 weeks ago • Molecular aspects of medicine

How Type 2 Diabetes Medicines May Affect Cancer TreatmentType 2 diabetes medications and their implications for cancer treatment: A comprehensive review.

🥉 Top 5% JournalArticle

3 weeks ago • JAMA network open

Reported Side Effects in Social Media Users Taking Unapproved RetatrutideSelf-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.

🥈 Top 2% JournalArticle

3 weeks ago • Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Use of GLP-1 receptor drugs and complications after body shaping surgery after major weight lossGLP-1 receptor agonist use and postoperative complications after body contouring surgery following massive weight loss.

📖 Top 30% JournalArticle

3 weeks ago • North American Spine Society journal

Effects of GLP-1 receptor agonists on spine fusion success, safety, and risks in planned spine surgeryGLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.

📖 Top 20% JournalArticle

3 weeks ago • European journal of pharmacology

Sitagliptin and GTS-21 together may improve blood sugar control and kidney damage by reducing cell death in diabetic miceEffects of sitagliptin combined with GTS-21 on improving glycemic control and diabetic nephropathy by anti-apoptosis in Leprdb/db mice.

📖 Top 20% JournalArticle

3 weeks ago • Drug design, development and therapy

Oral Obesity Drugs in Heart, Kidney, and Metabolic Conditions: Moving Beyond Weight Loss to Changing DiseaseOral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.

📖 Top 20% JournalArticle

3 weeks ago • Aesthetic surgery journal

Facial Changes Linked to Glucagon-Like Peptide-1 Receptor Agonists: Causes, Symptoms, Risks, Prevention, and TreatmentGlucagon-Like Peptide-1 Receptor Agonist-Associated Facial Changes: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Risk Factors, Prevention, and Management.

📖 Top 20% JournalArticle

← prevpage 8 of 16next →

GLP-1 Therapies Research Papers